Format

Send to

Choose Destination
Circ Res. 2013 Jan 4;112(1):174-94. doi: 10.1161/CIRCRESAHA.111.300271.

Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.

Author information

1
UCD Conway Institute and Java Clinical Research, University College Dublin, Ireland.

Abstract

The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck.

PMID:
23287454
PMCID:
PMC3572712
DOI:
10.1161/CIRCRESAHA.111.300271
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center